Ampligen (rintatolimod)

September 6, 2019September 6, 2019

Ampligen Combo Safe, Effective in Treating Recurrent Ovarian Cancer, Phase 1 Study Shows

News

A combination of Hemispherx Biopharma‘s investigational treatment Ampligen (rintatolimod) with chemo-immunotherapy is safe and effective in treating women with recurrent ovarian cancer, according to the final report of a Phase ... Read more

May 20, 2019

Ampligen Showing Promise for Recurrent Ovarian Cancer in Phase 1/2 Trial, Phase 2 Study Now Recruiting

News

Hemispherx Biopharma‘s experimental therapy Ampligen (rintatolimod) can change the tumor microenvironment to increase the amount of infiltrating T-cells, an approach that is showing promise in a Phase 1/2 clinical trial ... Read more